Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

but that was offset by higher rates of inflammatory reactions in the eyes – some of which could be sight threatening – compared to rival anti-VEGF therapy Eylea (aflibercept) from Bayer and ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

US sales alone rose 10%. EYLEA/EYLEA HD generated combined US sales of $1.5 billion in Q4, capturing 46% of the anti-VEGF (vascular endothelial growth factor) market, with EYLEA HD sales reaching ...

Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications ...

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...